316 related articles for article (PubMed ID: 33338329)
1. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
2. Fumarate Hydratase Mutations and Alterations in Leiomyoma With Bizarre Nuclei.
Zhang Q; Poropatich K; Ubago J; Xie J; Xu X; Frizzell N; Kim J; Kong B; Wei JJ
Int J Gynecol Pathol; 2018 Sep; 37(5):421-430. PubMed ID: 28863073
[TBL] [Abstract][Full Text] [Related]
3. Leiomyoma with nuclear atypia: Rare diseases that present a common diagnostic problem.
Wei JJ
Semin Diagn Pathol; 2022 May; 39(3):187-200. PubMed ID: 35144823
[TBL] [Abstract][Full Text] [Related]
4. Uterine Leiomyosarcoma Associated With Leiomyoma With Bizarre Nuclei: Histology and Genomic Analysis of 2 Cases.
Fischer JV; Mejia-Bautista M; Vadasz B; Yin P; Bulun S; Tanner EJ; Lu X; Wei JJ
Int J Gynecol Pathol; 2022 Nov; 41(6):552-565. PubMed ID: 35093974
[TBL] [Abstract][Full Text] [Related]
5. Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations.
Gregová M; Hojný J; Němejcová K; Bártů M; Mára M; Boudová B; Laco J; Krbal L; Tichá I; Dundr P
Pathol Oncol Res; 2020 Jul; 26(3):1527-1537. PubMed ID: 31471882
[TBL] [Abstract][Full Text] [Related]
6. Loss of dystrophin is common in uterine leiomyosarcoma: a potential biomarker for clinical application.
Vadasz B; Felicelli C; Feng Y; Yin P; Zhang Q; Bulun S; Wei JJ
Hum Pathol; 2023 Apr; 134():85-91. PubMed ID: 36549601
[TBL] [Abstract][Full Text] [Related]
7. MVP immunohistochemistry is a useful adjunct in distinguishing leiomyosarcoma from leiomyoma and leiomyoma with bizarre nuclei.
Lintel NJ; Luebker SA; Lele SM; Koepsell SA
Hum Pathol; 2018 Mar; 73():122-127. PubMed ID: 29307622
[TBL] [Abstract][Full Text] [Related]
8. Fumarase-deficient Uterine Leiomyomas: An Immunohistochemical, Molecular Genetic, and Clinicopathologic Study of 86 Cases.
Miettinen M; Felisiak-Golabek A; Wasag B; Chmara M; Wang Z; Butzow R; Lasota J
Am J Surg Pathol; 2016 Dec; 40(12):1661-1669. PubMed ID: 27454940
[TBL] [Abstract][Full Text] [Related]
9. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
[TBL] [Abstract][Full Text] [Related]
10. Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.
Liegl-Atzwanger B; Heitzer E; Flicker K; Müller S; Ulz P; Saglam O; Tavassoli F; Devouassoux-Shisheboran M; Geigl J; Moinfar F
Mod Pathol; 2016 Oct; 29(10):1262-77. PubMed ID: 27363490
[TBL] [Abstract][Full Text] [Related]
11. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma.
Zhang P; Zhang C; Hao J; Sung CJ; Quddus MR; Steinhoff MM; Lawrence WD
Hum Pathol; 2006 Oct; 37(10):1350-6. PubMed ID: 16949924
[TBL] [Abstract][Full Text] [Related]
12. Lung metastases and subsequent malignant transformation of a fumarate hydratase -deficient uterine leiomyoma.
Ahvenainen T; Khamaiseh S; Alkodsi A; Mehine M; Nevala R; Äyräväinen A; Bützow R; Vahteristo P
Exp Mol Pathol; 2022 Jun; 126():104760. PubMed ID: 35367216
[TBL] [Abstract][Full Text] [Related]
13. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
14. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
15. Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases.
Croce S; Young RH; Oliva E
Am J Surg Pathol; 2014 Oct; 38(10):1330-9. PubMed ID: 25140893
[TBL] [Abstract][Full Text] [Related]
16. Immunofluorescence analysis of DNA damage response protein p53-binding protein 1 in a case of uterine dedifferentiated leiomyosarcoma arising from leiomyoma.
Matsuda K; Akazawa Y; Yamaguchi Y; Mussazhanova Z; Kurohama H; Ueki N; Kohno M; Fukushima A; Kajimura I; Hiraki H; Matsuwaki T; Kawashita S; Kinoshita A; Nakashima M
Pathol Res Pract; 2019 Nov; 215(11):152640. PubMed ID: 31570279
[TBL] [Abstract][Full Text] [Related]
17. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
18. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics.
Watanabe K; Suzuki T
Histopathology; 2006 Apr; 48(5):563-8. PubMed ID: 16623782
[TBL] [Abstract][Full Text] [Related]
19. Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.
Fontanges Q; Dubos P; Lesluyes T; Laizet Y; Velasco V; Meléndez B; D'Haene N; Oliva E; Young RH; Mayeur L; Rebier F; Alamé M; Larmonier C; Devouassoux-Shisheboran M; Arnould L; Soubeyran I; Chakiba C; Floquet A; Babin G; Guyon F; Mery E; Le Guellec S; Noël JC; Croce S; Chibon F
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23229. PubMed ID: 38481055
[TBL] [Abstract][Full Text] [Related]
20. Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review.
Yanai H; Wani Y; Notohara K; Takada S; Yoshino T
Pathol Int; 2010 Jul; 60(7):506-9. PubMed ID: 20594271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
